Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 30

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 30
---
30.6% of the Group’s trade payables in aggregate. For both the years ended December 31, 2024 and 2023, no vendor contributed more than 10% of total direct cost of the Group. NewGenIvf’s procurement team is experienced in selecting cost-effective supplies as well as selecting reliable suppliers. NewGenIvf’s major suppliers are pharmaceutical companies. Competition NewGenIvf believes that it is a long-standing provider of ARS in Asia Pacific that competes primarily based on the following competitive factors:

| ● | the                                           
 value and comprehensiveness of the solutions; |

| ● | treatment                                        
 that is effective and achieves desired outcomes; |

| ● | clients’                                                                                    
 experience, including dedicated patient education, clinical guidance and emotional support; 
 and                                                                                         |

| ● | access                                              
 to a network of high-quality fertility specialists. |

NewGenIvf competes primarily with other regional fertility service providers. While NewGenIvf does not believe any single competitor offers a comparably robust and integrated fertility solution package as NewGenIvf in the regions that it operates, NewGenIvf’s competitors may compete in a variety of ways, including by providing better services, having established local connections, fulfilling evolving client needs, as well as conducting brand promotions and other marketing activities.

<div align='center'>16</div>

As NewGenIvf may introduce new ancillary services and other companies may introduce similar fertility services as NewGenIvf’s, NewGenIvf may become subject to additional competition. Facilities As of December 31, 2024, in addition to its clinics, NewGenIvf leased one property in Hong Kong with an aggregate square footage of approximately 8,000 for its administration support offices. NewGenIvf also operates its medical facilities as described above in “— Network of Facilities” above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs. Organizational Structure The following is a list of our principal subsidiaries and consolidated affiliated entities as of the date of this prospectus:

| Name                                                         
 NewGenIvf Limited                                            
 Incorporated on January 16, 2019                             |     | Place               
 of Formation        
 Cayman Islands      |     | Relationship                                           
 Wholly-owned subsidiary                                |
|:-------------------------------------------------------------|:----|:--------------------|:----|:-------------------------------------------------------|
| FFPGS (HK) Ltd                                               |     | Hong Kong           |     | Indirect subsidiary, wholly owned by NewGen